NCT03809364 is a NA clinical trial of START Together in Human Immunodeficiency Virus, sponsored by University of Maryland, College Park.

Who is sponsoring NCT03809364?

NCT03809364 is sponsored by University of Maryland, College Park.

What drugs are being tested in NCT03809364?

Interventions in NCT03809364: START Together.

What condition does NCT03809364 study?

NCT03809364 studies Human Immunodeficiency Virus.

Is NCT03809364 still recruiting?

NCT03809364 is currently completed. Last updated 27 December 2023.

Last reviewed 2023-12-27 · How we verify

NCT03809364

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Test of a Couple-Based Medication Adherence Intervention for HIV-Positive Women and Their Male Partners in South Africa

Completed NA Last updated 27 December 2023

What this trial tests

NA trial testing START Together in Human Immunodeficiency Virus in 40 participants. Completed in 15 December 2022.

Timeline

1 November 2021

Primary endpoint
11 October 2022

15 December 2022

Quick facts

Lead sponsor	University of Maryland, College Park
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 November 2021
Primary completion	11 October 2022
Estimated completion	15 December 2022
Sites	1 location across South Africa

Drugs / interventions tested

START Together

Conditions studied

Human Immunodeficiency Virus — all drugs for Human Immunodeficiency Virus →

Sponsor

University of Maryland, College Park

Who can join

18 and older, any sex, with Human Immunodeficiency Virus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to collect quantitative data related to developing and testing a couple-based intervention (CBI) for HIV-positive women's medication adherence in the region of Kwazulu-Natal, South Africa. The CBI, called START (Supporting Treatment for Anti-Retroviral Therapy) Together, will be a manualized intervention focused on women's ART adherence and enhancing the couple's communication and problem-solving behavior. The study focuses on implementation outcomes (feasibility, acceptability, and fidelity) and preliminary efficacy outcomes (women's ART adherence, men's engagement in HIV care, and the couple's relationship functioning), which will be compared to a control condition of referrals to usual HIV care.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Accuracy of measures for antiretroviral adherence in people living with HIV.
Smith R, Villanueva G, Probyn K, Sguassero Y, et al · · 2022 · cited 34× · PMID 35871531 · DOI 10.1002/14651858.cd013080.pub2
Feasibility and Acceptability Pilot Test of Connecting Latinos en Parejas: A Couples-Based HIV Prevention Intervention for Latino Male Couples.
Martinez O, Fernandez MI, Yang C, Wu E, et al · · 2023 · cited 6× · PMID 37096329 · DOI 10.1177/15579883231167106
Supporting Treatment for Anti-Retroviral Therapy (START) Together: Protocol for a pilot, randomized, couple-based intervention to promote women's ART adherence and men's engagement in HIV care in KwaZulu-Natal, South Africa.
Belus JM, van Heerden A, van Rooyen H, Bradley VD, et al · · 2022 · cited 2× · PMID 36105267 · DOI 10.1016/j.conctc.2022.100970
Couple-Based Intervention to Improve HIV Care Engagement for Women and their Partners in KwaZulu-Natal, South Africa: Outcomes of a Pilot Randomized Controlled Trial.
Belus JM, van Heerden A, Hines AC, Pita TP, et al · · 2025 · cited 1× · PMID 39871688 · DOI 10.1177/23259582241307694

Verify or expand the search:

Other recruiting trials for Human Immunodeficiency Virus

Currently open trials in the same condition.

NCT07530198 — HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong · Phase 1 · recruiting
NCT06819176 — Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretrovir · Phase 1 · recruiting
NCT06408142 — Universal Test and Connect for HIV Service Delivery in South Africa · recruiting
NCT07101458 — The Eswatini PRISM Study on Adolescents Living With HIV · NA · recruiting
NCT06554223 — The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care · NA · recruiting

Other University of Maryland, College Park trials

Trials by the same sponsor.

NCT07134543 — Using the Smart Underwear Device to Determine a Baseline of Flatus Activity Normalized to Fiber Intake · recruiting
NCT07162376 — How Clinical and Personal Information Shape Physicians' Risk Judgments · NA · completed
NCT06985641 — Khanya Ekhaya: A Home-Based Intervention · NA · not yet recruiting
NCT06724705 — Testing the Capability of the Smart Underwear Device to Detect Increased Microbiome Activity Following Lactose Consumpti · NA · recruiting
NCT06305039 — Optimizing Bilateral and Single-sided-deafness Cochlear Implants for Functioning in Complex Auditory Environments · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03809364 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, College Park
Last refreshed: 27 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03809364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing